Clinical Trial

Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females

Completed
View on ClinicalTrials.gov →
Summary
The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creatine concentrations, gastrointestinal symptomatology, and fluid distribution measured through bioelectrical impedance spectroscopy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-04; most recent amendment 2026-03-10.
Status change: Recruiting → Completed 2026-03-10
Status change: Not Yet Recruiting → Recruiting 2025-11-05
Trial Details
NCT Number NCT07225335
Lead Sponsor TSI Group LTD
Collaborators: University of North Carolina
Conditions Creatine Absorption in Healthy Adults
Enrollment 17 participants
Start Date 2025-11-05
Primary Completion 2025-12-19 (estimated)
Study Completion 2025-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-12